Figure 4.

TLR2 values were significantly elevated in patients with JAK2 V617F mutations and leukocytosis but not in patients with thrombocytosis or anemia. (a) Ninety patients with JAK2 V617F mutations were compared with 11 CALR mutations (including six Type 1 and five Type 2) (six ET and five PMF) and 21 controls. The mean TLR2 values were JAK2 V617F (305.0 ± 13.7), CALR mutations (262.8 ± 11.3), and controls (220.6 ± 9.8). Patients with JAK2 mutations had significantly elevated TLR2 values compared to controls (P=0.007), while JAK2 mutations were not significantly different from CALR mutations, and CALR mutation patients were not significantly different from controls. (b) TLR2 levels were significantly higher in patients with leukocytosis (>10 × 10⁹/l) than in patients without leukocytosis (333.0 ± 22.97 (n = 46) vs. 269 ± 14.45 (n = 36) (P=0.03). (c) TLR2 values were not significantly different in patients with thrombocytosis (>400 × 10¹²/l) vs. those without thrombocytosis. The mean TLR2 values were in patients with thrombocytosis (304.5 ± 16.5) (n = 55) vs. patients without thrombocytosis (251.2 ± 16.3) (n = 26) (P = NS). (d) TLR2 values were not significantly different in patients with anemia (men < 14 gm/ml, women < 13 gm/ml) compared to those without anemia (294.1 ± 13.9) (n = 46); (317.4 ± 35.6) (n = 37), respectively.